Integrated genomic profiling identifies two distinct molecular subtypes with divergent outcome in neuroblastoma with loss of chromosome 11q

[1]  Gudrun Schleiermacher,et al.  Overall genomic pattern is a predictor of outcome in neuroblastoma. , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[2]  John M. Maris,et al.  Identification of ALK as a major familial neuroblastoma predisposition gene , 2008, Nature.

[3]  Roland Eils,et al.  Subclassification and Individual Survival Time Prediction from Gene Expression Data of Neuroblastoma Patients by Using CASPAR , 2008, Clinical Cancer Research.

[4]  Rainer König,et al.  Distinct transcriptional MYCN/c-MYC activities are associated with spontaneous regression or malignant progression in neuroblastomas , 2008, Genome Biology.

[5]  N. Potter,et al.  Genomic deletions correlate with underexpression of novel candidate genes at six loci in pediatric pilocytic astrocytoma. , 2008, Neoplasia.

[6]  F. Westermann,et al.  Risk Estimation of Neuroblastoma Patients Using Molecular Markers , 2008, Klinische Padiatrie.

[7]  H. Tagawa,et al.  High-resolution analysis of DNA copy number alterations and gene expression in renal clear cell carcinoma. , 2008, The Journal of pathology.

[8]  G. Giaccone,et al.  Integration of Gene Dosage and Gene Expression in Non-Small Cell Lung Cancer, Identification of HSP90 as Potential Target , 2008, PloS one.

[9]  Andrew G. Hall,et al.  Identification of candidate genes involved in neuroblastoma progression by combining genomic and expression microarrays with survival data , 2007, Oncogene.

[10]  R. Stallings.  Origin and functional significance of large-scale chromosomal imbalances in neuroblastoma , 2007, Cytogenetic and Genome Research.

[11]  K. Cole,et al.  Neuroblastomas have distinct genomic DNA profiles that predict clinical phenotype and regional gene expression , 2007, Genes, chromosomes & cancer.

[12]  B. Hero,et al.  Neuroblastoma , 2007, The Lancet.

[13]  Roland Eils,et al.  Human Resting CD4+ T Cells Are Constitutively Inhibited by TGFβ under Steady-State Conditions12 , 2007, The Journal of Immunology.

[14]  Nallasivam Palanisamy,et al.  Targets of genome copy number reduction in primary breast cancers identified by integrative genomics , 2007, Genes, chromosomes & cancer.

[15]  F. Berthold,et al.  Oligonucleotide array‐based comparative genomic hybridization (aCGH) of 90 neuroblastomas reveals aberration patterns closely associated with relapse pattern and outcome , 2006, Genes, chromosomes & cancer.

[16]  Patrick Warnat,et al.  Customized oligonucleotide microarray gene expression-based classification of neuroblastoma patients outperforms current clinical risk stratification. , 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[17]  Antonio Ortega,et al.  Prognostic significance of gene expression profiles of metastatic neuroblastomas lacking MYCN gene amplification. , 2006, Journal of the National Cancer Institute.

[18]  Barbara Hero,et al.  Differential Expression of Neuronal Genes Defines Subtypes of Disseminated Neuroblastoma with Favorable and Unfavorable Outcome , 2006, Clinical Cancer Research.

[19]  H. Xiao,et al.  Correlation between genomic DNA copy number alterations and transcriptional expression in hepatitis B virus‐associated hepatocellular carcinoma , 2006, FEBS letters.

[20]  W. Gerald,et al.  Integrative genomics identifies distinct molecular classes of neuroblastoma and shows that multiple genes are targeted by regional alterations in DNA copy number. , 2006, Cancer research.

[21]  F. Berthold,et al.  Loss in Chromosome 11q Identifies Tumors with Increased Risk for Metastatic Relapses in Localized and 4S Neuroblastoma , 2006, Clinical Cancer Research.

[22]  John M Maris,et al.  High-resolution analysis of chromosomal breakpoints and genomic instability identifies PTPRD as a candidate tumor suppressor gene in neuroblastoma. , 2006, Cancer research.

[23]  Axel Benner,et al.  Reduced Expression of CAMTA1 Correlates with Adverse Outcome in Neuroblastoma Patients , 2006, Clinical Cancer Research.

[24]  Hiroyuki Shimada,et al.  Chromosome 1p and 11q deletions and outcome in neuroblastoma. , 2005, The New England journal of medicine.

[25]  John K Field,et al.  Quantitative high-throughput analysis of DNA methylation patterns by base-specific cleavage and mass spectrometry. , 2005, Proceedings of the National Academy of Sciences of the United States of America.

[26]  Qing-Rong Chen,et al.  Inferring a tumor progression model for neuroblastoma from genomic data. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[27]  S. Ishii,et al.  Expression profiling using a tumor-specific cDNA microarray predicts the prognosis of intermediate risk neuroblastomas. , 2005, Cancer cell.

[28]  K. Aldape,et al.  Integrated array-comparative genomic hybridization and expression array profiles identify clinically relevant molecular subtypes of glioblastoma. , 2005, Cancer research.

[29]  D Catchpoole,et al.  Oligonucleotide microarray analysis of gene expression in neuroblastoma displaying loss of chromosome 11q. , 2004, Carcinogenesis.

[30]  W. Gerald,et al.  Genome-wide analysis of gene expression associated with MYCN in human neuroblastoma. , 2003, Cancer research.

[31]  G. Brodeur.  Neuroblastoma: biological insights into a clinical enigma , 2003, Nature Reviews Cancer.

[32]  Holger Christiansen,et al.  Loss of a FYN-regulated differentiation and growth arrest pathway in advanced stage neuroblastoma. , 2002, Cancer cell.

[33]  Christian A. Rees,et al.  Microarray analysis reveals a major direct role of DNA copy number alteration in the transcriptional program of human breast tumors , 2002, Proceedings of the National Academy of Sciences of the United States of America.

[34]  Keith Wilson,et al.  Silence of chromosomal amplifications in colon cancer. , 2002, Cancer research.

[35]  P. Ambros,et al.  Pathology and biology guidelines for resectable and unresectable neuroblastic tumors and bone marrow examination guidelines. , 2001, Medical and pediatric oncology.

[36]  M. Schwab,et al.  Amplification of oncogenes revisited: from expression profiling to clinical application. , 2001, Cancer letters.

[37]  R. Tibshirani,et al.  Significance analysis of microarrays applied to the ionizing radiation response , 2001, Proceedings of the National Academy of Sciences of the United States of America.

[38]  M Schwab,et al.  N‐myc enhances the expression of a large set of genes functioning in ribosome biogenesis and protein synthesis , 2001, The EMBO journal.

[39]  F. Berthold,et al.  The international neuroblastoma risk groups (INRG): a preliminary report , 1997 .

[40]  R. Arceci.  The International Neuroblastoma Risk Group (INRG) Classification System: An INRG Task Force Report , 2009 .

[41]  F. Berthold,et al.  Deletions in chromosome arms 3p and 11q are new prognostic markers in localized and 4s neuroblastoma. , 2003, Clinical cancer research : an official journal of the American Association for Cancer Research.